Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Sep 10, 2024
Episode
244
Soundcloud
Share
In this special WCLC 2024 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap the conference and discuss the meeting's most impactful research. Dr. Jacob Sands discusses overall survival updates from TROPION-Lung01 with datopotamab deruxtecan and DeLLphi-301 with tarlatamab. Dr. Hidehito Horinouchi reports results from the LUMINOSITY study of telisotuzumab vedotin, and Dr. Noemi Reguart gives some perspective on TRUST-II with talectrectinib. The group discusses the biggest stories from WCLC 2024, their favorite moments, and a preview of WCLC 2025 in Barcelona, Spain.
Guest
Stephen Liu
MD
Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Hidehito Horinouchi
MD, PhD
Assistant Chief of the Department of Thoracic Oncology
National Cancer Center Hospital
Noemí Reguart
MD, PhD
Coordinator of the Thoracic Oncology; Clinical Professor
Hospital Clinic of Barcelona
University of Barcelona
Jacob Sands
MD
Assistant Professor of Medicine, Harvard Medical School
Lowe Cancer Center for Thoracic Oncology
Dana Farber Cancer Institute
